# Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Study · id `cardio:ct-nct05263778` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05263778](<https://clinicaltrials.gov/study/NCT05263778>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05263778

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT05263778. Randomized; quadruple masking; primary purpose prevention. Start 2022-03 (anticipated); primary completion 2023-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT05263778, source copy `cardio:ctgov-nct05263778-2022-03-03`, retrieved 2026-10-26)
- Planned start: 2022-03 (anticipated) (ClinicalTrials.gov record NCT05263778, source copy `cardio:ctgov-nct05263778-2022-03-03`, retrieved 2026-10-26)
- Primary completion: 2023-06 (anticipated) (ClinicalTrials.gov record NCT05263778, source copy `cardio:ctgov-nct05263778-2022-03-03`, retrieved 2026-10-26)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05263778, source copy `cardio:ctgov-nct05263778-2022-03-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05263778, source copy `cardio:ctgov-nct05263778-2022-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05263778-2022-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study
- Condition: Cardiovascular Diseases
- Condition: NSTEMI
- Condition: STEMI
- Intervention (Drug): Bempedoic Acid / Ezetimibe Oral Tablet
- Intervention (Drug): Placebo
- Lead sponsor: Kaiser Permanente
- Lead sponsor class: OTHER
- Collaborator: Esperion Therapeutics, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Kaiser Permanente (`cardio:org-kaiser-permanente`)
- Registry lists this organization as a collaborator: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)

## Provenance

Content hash: d79aa37f51cc6103b237bb9c4dabd81a9eea11ee536de58a53072441266a4d41
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
